Navigation Links
Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections
Date:9/6/2010

The United States must focus on conserving the use of antibacterial drugs, or face a public health crisis from rapidly rising rates of antibiotic-resistant infections, according to an analysis out today.

Evidence indicates that our nation's supply of antibiotics is being depleted by resistance, which occurs when infection-causing microbes mutate or change so that they no longer respond to widely-used treatments. Most proposals to solve this problem focus on giving pharmaceutical companies financial incentives to develop new drugs that could replace those that are no longer working.

But a new report published today in the September issue of Health Affairs suggests that approach won't work for long. New drugs will face microbial foes that figure out how to evade treatment, say two medical policy experts.

"This is a war we cannot win unless we adopt a two-pronged strategy: one that would boost the supply of new drugs and at the same time preserve the ones we have left," says Aaron Kesselheim, M.D., J.D., M.P.H., one of the paper's co-authors. He conducted the analysis of antibacterial drugs and their impact on public health through a grant from Public Health Law Research (PHLR), a national program of the Robert Wood Johnson Foundation (RWJF).

The current pharmaceutical reimbursement system gives companies an incentive to oversell antibiotics, says Kesselheim, who is also an instructor in medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital and Harvard Medical School in Boston. Companies that have spent large sums of money on research and development for a new drug often seek to turn a profit on that product as quickly as possiblebefore resistance sets in, he says.

But the practice of aggressively marketing antibiotics actually adds to the resistance problem, says co-author Kevin Outterson, J.D., a professor at Boston University Law School. Overselling and overuse create an environment in which microbes are awash in antibiotics, which speeds the process of resistance, he says.

"Right now, pharmaceutical companies are rewarded for actions that conflict with the public health goal of reducing antibiotic resistance," Outterson says. "That has to stop."

The analysis in Health Affairs crafts an innovative solution to the problem, one that gives pharmaceutical companies financial incentives to market drugs in a way that would keep resistance rates at low levels.

Specifically, Kesselheim and Outterson suggest that government experts study the rates of resistance and set "effectiveness targets" for newly approved antibiotics. To meet those goals, which the authors say would be based on factors related to the disease targeted by the antibiotic, such as lower resistance rates, drug companies would need to coordinate with physicians and hospitals so that the drugs are prescribed only when clinically indicated. Such action would remove the current incentive to oversell.

Companies that met the predetermined targets (achieved through responsible use of the drugs) would be rewarded. For example, the authors suggest that Medicare could pay a bonus to companies producing drugs that meet their resistance targets. Or policy-makers could grant such companies extended market exclusivity so they could continue to earn revenuesas long as the drug use remained within the target zone.

Such a policy could help slow development of resistance in microbes and ensure new antibiotics have a longer shelf life, a bonus that would help not just individual patients but society as a whole, Kesselheim and Outterson predict.

The authors, and other experts, say that the United States must adopt more comprehensive strategies that give drug companies and others incentives to reduce antibiotic resistance. For example, hospitals should be financially rewarded for adhering to strict infection-control practices, which can reduce the spread of antibiotic-resistant microbes, says Ramanan Laxminarayan, Ph.D., principal investigator for Extending the Cure, an RWJF-funded project on antibiotic resistance.


'/>"/>

Contact: Becky Wexler
bwexler@burnesscommunications.com
301-652-1558
Burness Communications
Source:Eurekalert

Related medicine news :

1. Pharmaceuticals: A market for producing lemons and serious harm
2. FDA approves Merz Pharmaceuticals Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm
3. The malicious use of pharmaceuticals: An under-recognized form of child abuse
4. Mary Hendrickson of GENCO Pharmaceutical Services Speaks Before Senate on the Topic of Drug Take-Back Programs
5. SDI Reports: Novo Nordisk Takes Top Ranking Among Endocrinologists, According To Pharmaceutical Company Image Study
6. Chinese Biopharmaceutical Association Successfully Holds 15th Annual Conference
7. Omega Design Presented Pharmaceutical Packaging Solutions at the Healthcare Packaging Conference & Workshop 2010
8. HR Pharmaceuticals, Inc. to Launch and Showcase Flagship Product Line at the National Teaching Institute & Critical Care Nurses Exposition
9. Pharmaceutical companies provide EPA 100 drugs to help predict toxicity
10. HIRC Research Alert: New Study Identifies Best Pharmaceutical Company Account Managers and Program Offerings
11. SDI Reports: Pharmaceutical Promotion Spending Indicates Trend Toward Electronic and Online Promotion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top ... and genders. And the need for advanced services is growing. , Project WE ... care program, in collaboration with their non-profit partners in their fight against cancer and ...
(Date:2/26/2017)... ... 2017 , ... NuevaCare, a leading home care agency based in San Mateo, ... is proud to announce an important upgrade to its geographic information pages, starting with ... to home, and by having city-specific pages, NuevaCare is answering that information need. , ...
(Date:2/26/2017)... ... ... ODH, Inc.™ announced today it will exhibit and speak at the ... in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present on ... health management. , ODH will also have an exhibit booth where attendees may speak ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, expert ... Core benefits and advantages built into the home office sit stand solution are ... feel. Ability to gain the benefits embedded in the TaskMate Go are available ...
(Date:2/24/2017)... ... 24, 2017 , ... An in-depth computational analysis of genetic variants implicated in ... eight genes that may explain why susceptibility to one of the disorders could place ... published today in the journal npj Schizophrenia. , “There is a wealth of ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Period October – December 2016 Revenues amounted to SEK ... million Result after tax amounted to SEK -16.3 (-6.5) million, ... Cash flow from operating activities amounted to SEK -8.3 (-7.3) million ... Period full year 2016 ... result amounted to SEK -39.5 (-29.5) million Result after tax ...
(Date:2/24/2017)... , Feb. 24, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the Cowen and ... the Boston Marriott Copley Place on Tuesday, March 7, ... A live webcast of the presentation can be accessed ... for replay following the conference via Zimmer Biomet,s Investor ...
(Date:2/24/2017)... Feb. 24, 2017  In conjunction with DURECT Corporation,s ... results press release, you are invited to listen to ... the internet on Tuesday, March 14, 2017 at 4:30 ... A live audio webcast of the presentation will be ... and clicking "Investor Relations."  If you are unable to ...
Breaking Medicine Technology: